About Prodesse
Prodesse is a Healthcare company based in Waukesha (United States) founded in 1985, and was acquired by Gen-Probe in October 2009. It operates as a molecular diagnostic reagents for infectious diseases are developed. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified. Its competitors include Inflammatix, BioLife Solutions, Visby Medical, Sino Biological and MeMed and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Prodesse was founded in 1985 and is headquartered in Waukesha, United States. Reagents for molecular diagnostics in infectious disease detection are created, including tests for human metapneumovirus, mycoplasma pneumoniae, chlamydophila pneumoniae, bordetella pertussis, toxigenic clostridium difficile, and parainfluenza virus. Contract research services and laboratory support are provided, with research-use kits and diagnostic kits available for sale.
- Headquarters Waukesha, United States
- Stage Acquired
- SectorsHealthcare
- Website prodesse.com
- Social LinkedIn X Facebook
- Acquired by Gen-Probe (Oct 2009)
Funding Insights of Prodesse
- Total Rounds 3
- Last Round Debt – Convertible — $751,431
- First Round $1.55M
(Jun 2002)
All 3 funding rounds of Prodesse with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2005 | $751,431 | Debt – Convertible | – | – | – |
| Nov 2004 | $1.2M | Unspecified | – | – | – |
| Jun 2002 | $1.55M | Unspecified | – | – | – |
1 investors in total: 1 institutional.
Investors in Prodesse
Prodesse has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Gen-Probe.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides clinical diagnostics, blood screening, and research products. | 1996 | gen-probe.com | San Diego, United States |
Investor details for Prodesse
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Prodesse
4 dated milestones of Prodesse across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Prodesse is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Debt – Convertible, of $751K.
- Exit Acquired by Gen-Probe.
Competitors of Prodesse
Prodesse has 10 listed competitors in our database, 9 of them funded. They include Inflammatix, BioLife Solutions, Visby Medical, Sino Biological and MeMed, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| biolifesolutions.com | 1987 | Bothell, United States | – | 685 | Tissue hypothermic storage and cryopreservation freeze media are developed. | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| me-med.com | 2009 | Tirat Carmel, Israel | $163M | – | Provider of machine learning based diagnostic solutions for infectious diseases | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| molbiodiagnostics.com | 2000 | Salcete, India | $123.98M | 714 | Point-of-care molecular platforms for infectious disease detection are developed. | |
| oncodna.com | 2012 | Charleroi, Belgium | $44.53M | 37 | Genomic and theranostic services for oncology precision medicine are delivered. | |
| fluentbio.com | 2018 | Watertown, United States | $19M | – | Proprietary reagents for single-cell genetic analysis are developed. |
Detailed competitors of Prodesse
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Prodesse (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Prodesse
Prodesse was founded in 1985 and raised its 1st funding round 17 years after it was founded.
Prodesse is headquartered in Waukesha, United States. It is registered at Waukesha, Wisconsin, United States.
Prodesse was founded in 1985 and is headquartered in Waukesha, United States. Reagents for molecular diagnostics in infectious disease detection are created, including tests for human metapneumovirus, mycoplasma pneumoniae, chlamydophila pneumoniae, bordetella pertussis, toxigenic clostridium difficile, and parainfluenza virus. Contract research services and laboratory support are provided, with research-use kits and diagnostic kits available for sale.
Prodesse's top competitors include Visby Medical, Inflammatix and MeMed.
Prodesse has 1 investor. Key investors include Gen-Probe.
Yes. Prodesse was acquired by Gen-Probe in October 2009.